648 related articles for article (PubMed ID: 26073023)
1. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
2. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
Arai K; Tsuruoka H; Homma T
Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
[TBL] [Abstract][Full Text] [Related]
3. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.
Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
J Pharmacol Sci; 2011; 115(3):346-53. PubMed ID: 21358118
[TBL] [Abstract][Full Text] [Related]
4. CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
Arai K; Morikawa Y; Ubukata N; Tsuruoka H; Homma T
J Pharmacol Exp Ther; 2016 Sep; 358(3):548-57. PubMed ID: 27384074
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
Bamberg K; Johansson U; Edman K; William-Olsson L; Myhre S; Gunnarsson A; Geschwindner S; Aagaard A; Björnson Granqvist A; Jaisser F; Huang Y; Granberg KL; Jansson-Löfmark R; Hartleib-Geschwindner J
PLoS One; 2018; 13(2):e0193380. PubMed ID: 29474466
[TBL] [Abstract][Full Text] [Related]
6. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
Eudy RJ; Sahasrabudhe V; Sweeney K; Tugnait M; King-Ahmad A; Near K; Loria P; Banker ME; Piotrowski DW; Boustany-Kari CM
J Transl Med; 2011 Oct; 9():180. PubMed ID: 22017794
[TBL] [Abstract][Full Text] [Related]
7. DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats.
Nariai T; Fujita K; Kawane K; Mori M; Nakayama R; Matsuda K; Katayama S; Fukuda N; Hori S; Iwata M; Hasegawa F; Suzuki K; Kato H
J Pharmacol Exp Ther; 2015 Jul; 354(1):2-9. PubMed ID: 25922341
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
9. Eplerenone: a new selective aldosterone receptor antagonist.
Weinberger MH
Drugs Today (Barc); 2004 Jun; 40(6):481-5. PubMed ID: 15349128
[TBL] [Abstract][Full Text] [Related]
10. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
[TBL] [Abstract][Full Text] [Related]
11. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Rogerson FM; Yao Y; Smith BJ; Fuller PJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
[TBL] [Abstract][Full Text] [Related]
12. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J
J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.
Liu S; Xie Z; Daugherty A; Cassis LA; Pearson KJ; Gong MC; Guo Z
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1568-79. PubMed ID: 23661677
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
Mihailidou AS; Mardini M; Funder JW; Raison M
Hypertension; 2002 Aug; 40(2):124-9. PubMed ID: 12154101
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
Takeda Y
Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
[TBL] [Abstract][Full Text] [Related]
20. Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats.
Rafiq K; Nakano D; Ihara G; Hitomi H; Fujisawa Y; Ohashi N; Kobori H; Nagai Y; Kiyomoto H; Kohno M; Nishiyama A
J Hypertens; 2011 Feb; 29(2):290-8. PubMed ID: 21243738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
